Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)

Next Previous
Trial Profile

A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iadademstat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Acronyms FiM
  • Sponsors Oryzon

    • Most Recent Events

    • 15 Oct 2020 According to an Oryzon media release, data from this study was published in Journal of Clinical Oncology.
    • 15 Oct 2020 Results published in the Oryzon Media Release
    • 30 Jan 2017 According to an Oryzon Genomics media release, top line results of this trial will be summarized at the Keystone Symposia on Epigenetics and Human Disease 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top